Evidence map›Paper›PMID 28925989›Full record

ArticleThe American journal of gastroenterology2018

Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD).

Fiona Taylor, Sophie Higgins, Robyn T Carson, Sonya Eremenco, Catherine Foley, Brian E Lacy, Henry P Parkman, David S Reasner, Alan L Shields, Jan Tack and 2 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in The American journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05846802 (Gastroparesis Registry 4), which is not on this map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05846802 recruitingnot on this mapstarted 2024, after this paper: background citation

Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan2024 to 2027Enrolled250ConditionsGastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus Type I, Gastroparesis Due to Diabetes Mellitus Type II
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

Fiona TaylorAdelphi Values, Patient-Centered Outcomes, Boston, Massachusetts, USA.
Sophie HigginsAdelphi Values, Patient-Centered Outcomes, Boston, Massachusetts, USA.
Robyn T CarsonAllergan Plc., Jersey City, New Jersey, USA.
Sonya EremencoCritical Path Institute, Tucson, Arizona, USA.
Catherine FoleyAdelphi Values, Patient-Centered Outcomes, Boston, Massachusetts, USA.
Brian E LacyDartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Henry P ParkmanTemple University School of Medicine, Philadelphia, Pennsylvania, USA.
David S ReasnerIronwood Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
Alan L ShieldsAdelphi Values, Patient-Centered Outcomes, Boston, Massachusetts, USA.
Jan TackUniversity of Leuven, Leuven, Belgium.
Nicholas J TalleyUniversity of Newcastle, Callaghan, New South Wales, Australia.
Patient-Reported Outcome Consortiumʼs Functional Dyspepsia Working Group
Adelphi Laboratory Center · USAllergan (United States) · USCritical Path Institute · USDartmouth–Hitchcock Medical Center · USIronwood Pharmaceuticals (United States) · USKU Leuven · BETemple University · USUniversity of Newcastle Australia · AU

Funding

Critical Path to Public Private PartnershipsU18FD005320 · FDA · CRITICAL PATH INSTITUTE · PI Klaus Romero · 2014 to 2026
$127.1M
FDA HHS U18 FD005320
6 · The paper itself

Abstract

objectivesThe Functional Dyspepsia Symptom Diary (FDSD) was developed to address the lack of symptom-focused, patient-reported outcome (PRO) measures designed for use in functional dyspepsia (FD) patients and meeting Food and Drug Administration recommendations for PRO instrument development.

methodsConcept elicitation interviews were conducted with FD participants to identify symptoms important and relevant to FD patients. A preliminary version of the FDSD was constructed, then completed by FD participants on an electronic device in cognitive interviews to evaluate the readability, comprehensibility, relevance, and comprehensiveness of the FDSD, and to preliminarily evaluate its measurement properties.

resultsDuring concept elicitation interviews, 45 participants spontaneously reported 19 symptom concepts. Of those, seven symptoms were selected for assessment by the eight-item FDSD. Cognitive interviews with 57 participants confirmed that participants were able to comprehend and provide meaningful responses to the FDSD, and that the handheld electronic FDSD format was suitable for use in the target population. Scores of the FDSD were well-distributed among response options, item discrimination indices suggested that the FDSD items differentiate among patients with varying degrees of FD severity, and inter-item correlations suggested that no items of the FDSD were capturing redundant information. Internal consistency estimates (0.87) and construct-related validity estimates using known-groups methods were within acceptable ranges.

conclusionsThe FDSD is a content-valid PRO measure, with preliminary psychometric evidence providing support for the FDSD's items and total score. Further psychometric evaluations are recommended to more fully test the FDSD's score performance and other measurement properties in the target patient population.

Indexed as

Patient Reported Outcome MeasuresAdultAgedComprehensionDyspepsiaFemaleHumansInterviews as TopicMaleMiddle AgedPsychometricsQuality of LifeReproducibility of ResultsSurveys and QuestionnairesYoung Adult

Identifiers

PMID28925989
PMCPMC5770596
OpenAlexW2756211321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.